Table 3.
Assessments of AMSTAR scores and GRADE classification for each outcome.
| Outcome | Author and year | Category | AMSTARa Score | GRADEb quality |
|---|---|---|---|---|
| Significant associations | ||||
| Breast cancer | Takkouche, B, 2009 | Overall NSAIDsd | 8 | very low |
| CNSc cancer | Zhang T,2017 | Overall NSAIDs | 8 | low |
| Esophageal cancer | Sun, 2011 | Overall NSAIDs | 7 | very low |
| Gastric cancer | Tian, 2010 | Overall NSAIDs | 9 | very low |
| Head and neck cancer | Shi, 2017 | Overall NSAIDs | 9 | moderate |
| Liver cancer | Pang, 2017 | Overall NSAIDs | 9 | very low |
| Prostate cancer | Shang, 2018 | Overall NSAIDs | 10 | very low |
| Skin cancer | Muranushi, 2014 | Overall NSAIDs | 7 | very low |
| Digestive system cancer incidence | Bosetti C, 2020 | Aspirin | 7 | very low |
| Breast cancer | Ma, 2021 | Aspirin | 9 | low |
| Cholangiocarcinoma | Lapumnuaypol, 2019 | Aspirin | 9 | very low |
| Colorectal cancer | Ye,2013 | Aspirin | 8 | moderate |
| Endometrial cancer | Zhang, 2016 | Aspirin | 9 | very low |
| Esophageal cancer | Sivarasan N, 2013 | Aspirin | 6 | very low |
| Gastric cancer | Win TT, 2020 | Aspirin | 9 | very low |
| Hepatocellular carcinoma | Wang, 2022 | Aspirin | 8 | very low |
| Lung cancer | Friederike, 2016 | Aspirin | 8 | very low |
| Ovary cancer | Zhang, 2016 | Aspirin | 9 | low |
| Prostate cancer | Shang, 2018 | Aspirin | 10 | very low |
| Pancreatic cancer | Bosetti C, 2020 | Aspirin | 8 | very low |
| CNS cancer | Zhang, 2017 | NA-NSAIDse | 9 | low |
| Colorectal cancer | Tomic, T, 2019 | NA-NSAIDs | 9 | very low |
| Esophageal cancer | Sun, 2011 | NA-NSAIDs | 7 | very low |
| Gastric cancer | Tian, 2010 | NA-NSAIDs | 9 | very low |
| Kidney cancer | Toni K, 2013 | NA-NSAIDs | 8 | very low |
| Skin cancer | Muranushi, 2015 | NA-NSAIDs | 7 | low |
| Non-Significant associations | ||||
| Pancreatic cancer | Zhang, 2015 | Overall NSAIDs | 8 | low |
| Cholangiocarcinoma | Lapumnuaypol, K,. 2019 | Overall NSAIDs | 9 | very low |
| Colon cancer | Harewood, 2021 | Overall NSAIDs | 10 | very low |
| Melanoma | Li, 2013 | Overall NSAIDs | 9 | very low |
| Non-Hodgkin's lymphoma | Bernatsky, S, 2007 | Overall NSAIDs | 5 | very low |
| Lung cancer | Xu, 2012 | Overall NSAIDs | 7 | very low |
| Bladder cancer | Zhang, 2013 | Aspirin | 7 | very low |
| CNS cancer | Liu, 2014 | Aspirin | 9 | low |
| Head and neck cancer | Tang, 2016 | Aspirin | 9 | very low |
| Kidney cancer | Choueiri, T, 2014 | Aspirin | 8 | very low |
| Melanoma | Li, 2013 | Aspirin | 9 | very low |
| Skin cancer | Muranushi, 2014 | Aspirin | 9 | very low |
| Bladder cancer | Zhang, 2013 | NA-NSAIDs | 7 | very low |
| Breast cancer | María, 2015 | NA-NSAIDs | 7 | very low |
| Endometrial cancer | Verdoodt, 2016 | NA-NSAIDs | 8 | very low |
| Head and neck cancer | Saka-Herran, 2021 | NA-NSAIDs | 9 | very low |
| Hepatocellular carcinoma | Liu, 2022 | NA-NSAIDs | 8 | very low |
| Lung cancer | Xu, 2012 | NA-NSAIDs | 9 | very low |
| Melanoma | Li, 2013 | NA-NSAIDs | 9 | very low |
| Ovary cancer | Baandrup, 2013 | NA-NSAIDs | 6 | very low |
| Pancreatic cancer | Zhang, 2015 | NA-NSAIDs | 8 | very low |
| Prostate cancer | Shang, 2018 | NA-NSAIDs | 10 | very low |
a
AMSTAR, a measurement tool to assess systematic reviews.
b
GRADE, Grading of Recommendations Assessment, Development, and Evaluation.
c
CNS, central nervous system.
d
NSAIDs: nonsteroidal anti-inflammatory drugs.
e
NA-NSAIDs:non-aspirin nonsteroidal anti-inflammatory drugs.